With another turbulent year behind us, we look ahead to the pharma trends that we believe will shape the industry in 2017.
We are witnessing an increasingly challenging payer environment, with elements of value-based pricing being introduced in many markets. This means that optimising your market access effort and aligning activities across markets is more important than ever. At the same time, the rise of the emerging markets (where the real growth potential is) means that global market access teams are looking after a wider range of markets.
So how do you ensure your company has the competitive edge to bring your medicine to market quickly, efficiently and with fewer restrictions?
Across the world, pharma companies of all sizes are still using a patchwork of non-specialised tools, typically Microsoft Excel, to organise their market access and launch efforts, with these files often shared across global and country teams in a SharePoint environment.
Launching a new medicine is a complex process that requires carefully aligned, coordinated and sequenced activities to take place across markets. Much like sailing a ship, successful and efficient voyages into the pharma market require pharma teams and their leaders to have the right tools, processes and information to get the job done.
If you're wondering why your current pharma launch readiness strategy isn't working as well as it could, here are some signs that your launch planning and execution tools might not be fit for purpose…